Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand
View original at seekingalpha.com“The year ended with $24.1 million in cash and $29.4 million in working capital.”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Planning to increase sales force to be ramped up no later than the first part of Q3
60% confidenceEmrosi achieved $14.7 million in net sales during the 3 quarters it was commercially available in 2025
60% confidence2025 was a milestone year with successful launch of Emrosi
60% confidenceTotal net product revenue growth was 11% with gross margin improvement of nearly 3.5 percentage points versus 2024
60% confidenceOne or two product launches likely in the second half of 2026 with expenses already included in budget
60% confidenceApproximately 100 million commercial covered lives have access to Emrosi
60% confidencePrescription volume for Emrosi grew nearly 50% sequentially in Q4 versus Q3
60% confidenceCompany expects improved reimbursement rates, reduced reliance on co-pay bridging program, and increase in Emrosi sales and operating margin expansion in 2026
60% confidenceMarch prescriptions rebounded and Q1 prescriptions expected to surpass Q4 numbers
60% confidenceJourney is well positioned to execute business plan and grow sales and profitability with current resources
60% confidenceTotal revenues for 2025 were $61.9 million, representing a 10% increase compared to $56.1 million for 2024
60% confidenceOver 3,500 unique dermatology prescribers had written at least one script for Emrosi by year end
60% confidenceGross to net expected to improve gradually quarter-over-quarter throughout 2026 as national formularies adopt Emrosi
60% confidence